Peruvoside

SKU: orb1990657

Description

Peruvoside is a cardiac glycoside that acts as a Na+/K+-ATPase inhibitor and a Src kinase inhibitor. It enhances myocardial contractility and exhibits anticancer activity by inducing cell cycle arrest and apoptosis via MAPK, Wnt/β-catenin, and PI3K/AKT/mTOR pathways in leukemia and NSCLC models, as demonstrated in in vitro studies.

Research Area

Cardiovascular Research, Cell Biology, Pharmacology & Drug Discovery, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1182-87-2
• MW: 548.67
• Purity: 98.96% (May vary between batches)
• Formula: C₃₀H₄₄O₉
• SMILES: C(=O)[C@@]12[C@@]3([C@]([C@]4(O)[C@](C)(CC3)[C@H](CC4)C=5COC(=O)C5)(CC[C@@]1(C[C@@H](O[C@H]6[C@@H](O)[C@H](OC)[C@@H](O)[C@H](C)O6)CC2)[H])[H])[H]
• Target: Src,ATPase,EGFR,Apoptosis,JNK,Wnt/beta-catenin,STAT,PI3K,Autophagy
• Solubility: DMSO:200 mg/mL (364.52 mM)

Bioactivity

• In Vivo:
  Methods: Nude mice with A549 cell subcutaneous xenografts were treated with Peruvoside (0.1 mg/kg, intraperitoneal injection, daily, for 28 days). Tumor growth was then monitored every 7 days. Results: The mean tumor size in the Peruvoside-treated group was 129.9 mm³ (95% CI = 86-174 mm³; P = 0.0068), which was significantly smaller than that in the control group (348 mm³, 95% CI = 189-507 mm³). The tumor weight was also significantly reduced, from 0.55 g in the control group to 0.26 g in the Peruvoside-treated group (P = 0.0126).
  Read more...
• In Vitro:
  Methods: A549 lung cancer cell line was treated with Peruvoside (5, 10, 50 nM, 24 hours), and the expression of related proteins was analyzed by Western Blot. Results: Peruvoside inhibited the protein expression and phosphorylation of Src, EGFR and STAT3 in A549 cells.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Encordin

Compound Identifiers

PubChem CID

12314120